Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations
Moderna has secured US Food and Drug Administration (FDA) approval for its mRNA influenza vaccine, overcoming initial data qualms from…
07 Aug 2026
Evotec and Odyssey collaborate on AI-enabled R&D
Evotec and Odyssey Therapeutics have announced a strategic AI-enabled research and development (R&D) partnership to explore new treatments for autoimmune and inflammatory diseases. This collaboration will focus on utilising Evotec’s data-driven…
07 Aug 2026
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases. These conditions often result in organ failure due to myofibroblast activation,…
06 Aug 2026
Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead
The US Food and Drug Administration (FDA) has approved Takeda’s oral orexin receptor agonist, oveporexton, for a form of narcolepsy – opening up the market for a drug class that…
06 Aug 2026
Eli Lilly raises 2026 outlook again as Q2 soars past estimates
Eli Lilly has lifted its full-year outlook for the second time this year on the back of another strong quarter, indicating it is far from relinquishing its dominant position as…
06 Aug 2026
Alteogen signs $365m Hybrozyme licensing deal with pharma company
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using…
06 Aug 2026
Schrödinger and BMS expand partnership to deploy AI for drug discovery
Schrödinger has entered a strategic agreement with Bristol Myers Squibb (BMS) to integrate its AI-based co-scientist platform Bunsen into BMS’s research operations. This initiative builds on an established partnership between…